Mechanism of Action: Nucleic Acid Synthesis Inhibitors
✉ Email this page to a colleague
Drugs with Mechanism of Action: Nucleic Acid Synthesis Inhibitors
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sandoz | ARRANON | nelarabine | INJECTABLE;INTRAVENOUS | 021877-001 | Oct 28, 2005 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Accord Hlthcare | AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 207475-001 | Jul 2, 2018 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Amneal | AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 211549-001 | Feb 3, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Natco Pharma Ltd | AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 207234-001 | Jun 23, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Eugia Pharma | AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 215066-001 | Dec 30, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |